Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival
- Author(s)
- Mendis, S; Beck, S; Lee, B; Lee, M; Wong, R; Kosmider, S; Shapiro, J; Yip, D; Steel, S; Nott, L; Jennens, R; Lipton, L; Burge, M; Field, K; Ananda, S; Wong, HL; Gibbs, P;
- Journal Title
- Asia Pacific Journal of Clinical Oncology
- Publication Type
- Journal Article in press
- Abstract
- BACKGROUND: Metastatic colorectal cancer (mCRC) patients with a right-sided primary (RC) have an inferior survival to mCRC arising from a left-sided primary (LC). Previous analyses have suggested multiple factors contribute. METHODS: The Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) Registry prospectively captured data on consecutive mCRC patients. RC were defined as tumors proximal to the splenic flexure; LC were those at and distal to the splenic flexure and included rectal cancers. Patient, tumor, treatment, and survival data were analyzed stratified by side. RESULTS: Of 2306 patients enrolled from July 2009-March 2018, 747 (32%) had an RC. Patients with RC were older, more likely to be female and have a Charlson score >/=3. RC were more frequently BRAF mutated, deficient in mismatch repair, associated with peritoneal metastases, and less likely to receive chemotherapy. Progression-free survival on first-line systemic therapy was inferior for RC patients (8.1 vs. 10.8 months, hazard ratio [HR] for progression in RC 1.38, P < 0.001). Median overall survival for all RC patients was inferior (19.6 vs. 27.5 months, HR for death in RC 1.44, P < 0.001), and inferior within the treated (21 vs. 29.5 months, HR 1.52, P < 0.001) and untreated subgroups (5.9 vs. 10.3 months, HR 1.38, P = 0.009). Primary side remained a significant factor for overall survival in multivariate analysis. CONCLUSION: Our data from a real-world population confirms the poorer prognosis associated with RC. Primary tumor location remains significantly associated with overall survival even when adjusting for multiple factors, indicating the existence of further side-based differences that are as yet undefined.
- Publisher
- Wiley
- Research Division(s)
- Personalised Oncology
- PubMed ID
- 30761750
- Publisher's Version
- https://doi.org/10.1111/ajco.13135
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2019-03-13 11:54:11
Last Modified: 2019-03-13 02:30:09